Boehringer Ingelheim will pay mRNA drug developer CureVac up to €465m ($600m) for an exclusive global license and development collaboration on CureVac’s potential mRNA vaccine in early clinical development for the treatment of lung cancer.
Sanofi and Regeneron may overtake Roche and Astrazeneca at the head of the increasingly monoclonal antibody (mAb) dominated asthma treatment market according to an industry analyst.
A candidate Ebola vaccine that uses Immunovaccine's formulation technology has stopped cynomolgus monkeys from catching the disease in a preclinical study.
Johnson & Johnson subsidiary Janssen has acquired monoclonal antibody (mAb) platform FynomAb through its purchase of private Swiss biopharma company Covagen.
Redbiotec has selected GE Healthcare’s single-use processing offering to aid development of its Herpesvirus vaccines which use viral antigen complexes and virus-like particles.
Specialty vaccine company PaxVax has acquired the oral typhoid vaccine Vivotif from Crucell, as well as its manufacturing facility in Thörishaus, Switzerland. Financial terms of the transaction were not disclosed.
Swiss-based Mymetics has agreed with Australian biotech Imugene to manufacture and develop its cancer immunotherapy HER-Vaxx, which is expected to enter into a Phase I/II clinical trial in 2015.
Ono Pharmaceuticals has received approval for Opidvo (Nivolumab) in Japan becoming the first biopharma to bring a fully human PD-1 monoclonal antibody to market.
The European Medicines Agency’s Committee for Advanced Therapies (CAT) has revised a reflection paper on the classification of advanced-therapy medicinal products (ATMPs) to reflect cases in which medicines can be classified as ATMPs.
Antitope will develop a manufacturing cell line for the Baylor Institute for Immunology Research’s (BIIR) novel dendritic-cell-targeting vaccine for the treatment of head and neck and cervical cancer.
The latest generation of “biobetters” which are engineered to be more effective than branded biologics are hitting the market before biosimilars and could make development of the latter pointless, an expert has said.
Development of new anti-choloesterol drugs containing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibiting monoclonal antibodies could double Repligen Bioprocessing’s earning power, according to a Jefferies analyst.
Aspyrian Therapeutics has teamed up with Goodwin Biotech to make antibody-drug conjugates (ADCs) with a technology platform that uses near‐infrared (NIR) light to activate the cytotoxin.
An expression system developed by Cevec Pharmaceuticals has achieved 'very high' titres and bypassed problems that beset other platforms, moving the possibility of a commercial respiratory syncytial virus (RSV) one step closer.
CMO Cytovance Biologics has entered into a manufacturing agreement with Pamlico Biopharma to develop a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections.
Novartis says the acquisition of Massachusetts-based biotech firm CoStim will accelerate its cancer immunotherapy programme but will not add any new technology.
Scientists at Caltech have published a study in Nature Medicine this week demonstrating that a gene therapy technique that boosts a mouse’s protection against HIV also works against HIV that’s transmitted via mucosal surfaces.
The evaluation of Genmab’s Duobody platform for the discovery and development of bispecific antibodies strengthens Eli Lilly’s biologics programme, the firm says.
Brad Pitt made himself sick to avoid a zombie virus in World War Z but, despite some real world precedents, he was lucky his gamble paid off according to virus experts we asked.
Pfenex has selected Paragon Bioservices to manufacture its Recombinant Protective Antigen (rPA) for an anthrax vaccine as it enters Phase I clinical trials.
Stada Arzneimittel has licensed European rights to a biosimilar version of the white blood cell booster filgrastim from Apotex and says it is not worried by competitors already in the market.
OncoMed Pharmaceuticals announced last week that the US Patent and Trademark Office granted its first US patent for technology to identify mAbs (monoclonal antibodies).
MIT engineers have developed a new nanoparticle that can protect a vaccine long enough to generate a strong immune response on mucosal surfaces far from the vaccination site.
The US Department of Health and Human Services (HHS) says it is buying cell lines to manufacture anthrax antitoxins on top of its $196m (€145m) deal with GlaxoSmithKline to stockpile Raxibacumab.
A new platform to help biopharma companies discover antibodies is also helping them go after more difficult targets and earn more collaborations with top biopharma companies.
Roche has agreed to research, develop and commercialize Inovio Pharmaceuticals' vaccine delivery tech as well as its multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.
A newly developed implantable melanoma vaccine is now in Phase I clinical trials thanks to the efforts of a cross-disciplinary team of engineers, scientists and clinicians from Harvard University and the Dana-Farber Cancer Institute.
Large arrays of identical nanosensors could improve MAb production, identify glycosylation and pinpoint the best cell lines for biomanufacturing say US researchers.
PharmAthene and Theraclone Sciences announced plans to merge and continue the joint development of monoclonal antibodies (mAbs) and vaccines on the verge of progressing to Phase II and III trials.
GlaxoSmithKline says MAbs (monoclonal antibodies) will play an important part in its future pipeline as it licenses and internalizes a discovery tech platform from Adimab.